We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Elevance Health (ELV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
Elevance Health (ELV - Free Report) reported $50.09 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 12%. EPS of $6.03 for the same period compares to $8.37 a year ago.
The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $49.52 billion. With the consensus EPS estimate being $4.98, the EPS surprise was +21.08%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Elevance Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Total Medical Membership: 45.37 million compared to the 45.62 million average estimate based on 18 analysts.
Medical Membership - Medicaid: 8.65 million versus the 18-analyst average estimate of 8.68 million.
Medical Membership - Medicare - Medicare Supplement: 877 thousand versus 867.33 thousand estimated by 18 analysts on average.
Medical Membership - Commercial Risk-Based - Employer Group Risk-Based: 3.62 million versus 3.62 million estimated by 18 analysts on average.
Revenues- Service fees: $2.14 billion versus the 18-analyst average estimate of $2.07 billion. The reported number represents a year-over-year change of +5.6%.
Revenues- Premiums: $41.79 billion versus $41.04 billion estimated by 18 analysts on average. Compared to the year-ago quarter, this number represents a +13.5% change.
Revenues- Net investment income: $625 million versus the 18-analyst average estimate of $449.12 million. The reported number represents a year-over-year change of +13.4%.
Revenues- Product revenue: $6.16 billion versus $6.34 billion estimated by 18 analysts on average. Compared to the year-ago quarter, this number represents a +4.6% change.
Total operating revenue- Carelon Services: $7.32 billion compared to the $7.46 billion average estimate based on 17 analysts. The reported number represents a change of +57.9% year over year.
Total operating revenue- CarelonRx: $11 billion compared to the $10.52 billion average estimate based on 17 analysts. The reported number represents a change of +20.3% year over year.
Total operating revenue- Health Benefits: $42.25 billion versus the 17-analyst average estimate of $41.54 billion. The reported number represents a year-over-year change of +10.4%.
Total operating revenue- Eliminations: $-10.63 billion compared to the $-10.14 billion average estimate based on 17 analysts. The reported number represents a change of +43.4% year over year.
Shares of Elevance Health have returned +11.4% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Elevance Health (ELV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Elevance Health (ELV - Free Report) reported $50.09 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 12%. EPS of $6.03 for the same period compares to $8.37 a year ago.
The reported revenue represents a surprise of +1.15% over the Zacks Consensus Estimate of $49.52 billion. With the consensus EPS estimate being $4.98, the EPS surprise was +21.08%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Elevance Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Elevance Health here>>>
Shares of Elevance Health have returned +11.4% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.